

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 under  
the Securities Exchange Act of 1934**

For the month ended July , 2013

**ICON plc**  
(Registrant's name)

0-29714  
(Commission file number)

South County Business Park, Leopardstown, Dublin 18, Ireland  
(Address of principal executive offices)

Brendan Brennan, CFO  
South County Business Park Leopardstown, Dublin 18, Ireland.  
Brendan.Brennan@iconplc.com  
0011-353-1-291-2000

(Name, telephone number, email and/or facsimile number and address of Company contact person)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Yes  No

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes  No

Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes  No

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82 **N/A**

---

**EXHIBIT LIST**

Exhibit      Description

99.1            ICON plc Press Release issued July 23, 2013

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ICON plc**

Date: July 23, 2013

/s/ Brendan Brennan  
Brendan Brennan  
Chief Financial Officer

## ICON shareholders vote in favour of all resolutions at its Annual General Meeting

DUBLIN--(BUSINESS WIRE)--July 23, 2013--**ICON plc, (NASDAQ: ICLR)**, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that all resolutions at the Annual General Meeting of the Company (AGM) held on 22<sup>nd</sup> July 2013 (which resolutions had all been recommended by the Board) were all duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders on 14<sup>th</sup> June 2013 and are available on the ICON plc website.

The final results of voting on each of the items submitted to a vote of shareholders during the AGM are as follows:

| RESOLUTION NUMBER | RESOLUTION  | TOTAL NUMBER OF VOTES | VOTE FOR   | VOTE AGAINST | VOTE WITHHELD |
|-------------------|---|-----------------------|------------|--------------|---------------|
| 1.1               | To re-elect Mr. Thomas Lynch                                | 51,674,203            | 51,474,431 | 133,020      | 66,752        |
| 1.2               | To re-elect Mr. Declan McKeon                               | 51,674,203            | 51,506,997 | 100,445      | 66,761        |
| 1.3               | To re-elect Prof. William Hall                              | 51,674,203            | 51,517,884 | 89,558       | 66,761        |
| 2                 | To receive accounts and reports                             | 51,674,203            | 51,409,116 | 8,517        | 256,570       |
| 3                 | To authorise the fixing of the auditors' remuneration       | 51,674,203            | 47,640,947 | 3,965,491    | 67,765        |
| 4                 | To authorise the Company to allot shares                    | 51,674,203            | 44,580,855 | 7,013,214    | 80,134        |
| 5**               | To disapply pre-emption rights                              | 51,674,203            | 45,337,820 | 6,251,874    | 84,509        |
| 6**               | To authorise the Company to make market purchases of shares | 51,674,203            | 51,122,122 | 13,329       | 538,752       |

\*\* Special Resolution. All resolutions are ordinary resolutions unless otherwise stated.

The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. In addition to the matters described in this press release, the ability to maintain large client contracts or enter into new contracts, maintain client relationships and the ability to manage the opening of new offices, the integration of new business mergers and acquisitions, as well as other risks and uncertainties detailed from time to time in reports filed with the US Securities and Exchange Commission by ICON, including its Form 20-F, F-1, S-8 and F-3, may affect the actual results achieved by ICON. ICON disclaims any intent or obligation to update these forward-looking statements.

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 78 locations in 37 countries and has approximately 10,170 employees. Further information is available at [www.iconplc.com](http://www.iconplc.com).

**ICON/ICLR-F**

CONTACT:

ICON

Investor Relations

1-888-381-7923

or

Brendan Brennan

Chief Financial Officer

+ 353 -1-291-2000

or

Simon Holmes

EVP Investor Relations and Corporate Development

+ 353 -1-291-2000